Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Teijin Pharma has entered into several distributorship agreement in Turkey, Mexico and the Caribbean and Middle East and North African (MENA) region, to expand the global marketing of its hyperuricemia and gout treatment,TMX-67 (febuxostat).
Subscribe to our email newsletter
The company has signed a deal with Menarini for Turkey market, which has been already marketing TMX-67 under the brand name Adenuric in Europe since March 2010 under marketing rights granted by licensee Ipsen.
Under the agreement with Takeda Pharmaceuticals North America (TPNA), Teijin Pharma is looking forward to expand its TMX-67 marketing in Mexico and Caribbean countries including Dominican Republic and Jamaica. Commercial launches in these new markets are expected in 2012 or later.
For the MENA region, Teijin Pharma has signed an agreement with Algorithm SAL of Lebanon, which has exclusive marketing rights to TMX-67 in 16 MENA countries, including Lebanon, Saudi Arabia and Egypt. Commercial launches are expected in 2012 or later.